Zoledronic acid

Generic Name
Zoledronic acid
Brand Names
Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
Drug Type
Small Molecule
Chemical Formula
C5H10N2O7P2
CAS Number
118072-93-8
Unique Ingredient Identifier
70HZ18PH24
Background

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...

Indication

Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...

Associated Conditions
Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
Associated Therapies
Bone Mineral Density

Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients

Phase 4
Conditions
Interventions
First Posted Date
2009-06-03
Last Posted Date
2010-02-17
Lead Sponsor
Korean Breast Cancer Study Group
Target Recruit Count
237
Registration Number
NCT00912938
Locations
🇰🇷

Department of Surgery, Korea University Guro Hospital, Seoul, Korea, Republic of

A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-05-29
Last Posted Date
2017-03-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
118
Registration Number
NCT00909961
Locations
🇹🇷

Novartis Investigative site, Konya, Turkey

🇹🇷

Novartis Investigational site, Istanbul, Turkey

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

First Posted Date
2009-05-18
Last Posted Date
2016-04-18
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
17
Registration Number
NCT00903162
Locations
🇺🇸

University of Colorado, Denver, Colorado, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Newton Wellesley Hospital, Newton, Massachusetts, United States

and more 1 locations

Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2009-05-04
Last Posted Date
2014-09-22
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
24
Registration Number
NCT00892242
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2009-04-29
Last Posted Date
2016-01-26
Lead Sponsor
Leiden University Medical Center
Target Recruit Count
15
Registration Number
NCT00889590
Locations
🇳🇱

Leiden University Medical Center, Leiden, Netherlands

🇧🇪

University hospital Gent, Gent, Belgium

🇳🇱

Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

and more 1 locations

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

First Posted Date
2009-04-21
Last Posted Date
2023-04-10
Lead Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Target Recruit Count
29
Registration Number
NCT00885326
Locations
🇨🇦

CHU Sainte Justine, Montreal, Quebec, Canada

🇺🇸

Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States

🇺🇸

Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States

and more 12 locations

A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

First Posted Date
2009-04-09
Last Posted Date
2019-06-13
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
5
Registration Number
NCT00879034
Locations
🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Withdrawn
Conditions
First Posted Date
2009-04-02
Last Posted Date
2013-04-10
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT00873808
Locations
🇺🇸

University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

First Posted Date
2009-03-25
Last Posted Date
2018-11-07
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1822
Registration Number
NCT00869206
Locations
🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

CCOP - Columbus, Columbus, Ohio, United States

and more 497 locations
© Copyright 2024. All Rights Reserved by MedPath